Finnish study: jaw osteonecrosis found in 12.6% of breast cancer patients treated with denosumab
- A University of Oulu registry study followed 652 women with breast cancer that had spread to the bones.
- Jaw osteonecrosis was diagnosed in 12.6% of patients treated with denosumab alone.
- The figure was 15.3% in patients who switched from bisphosphonates to denosumab.
- Tooth extraction and root canal treatment were associated with higher risk, underlining the need for dental care before and during treatment.
Antiresorptive drugs, which slow bone breakdown, are an important part of treatment for breast cancer that has spread to the bones. A known side effect is medication-related osteonecrosis of the jaw (MRONJ), in which jawbone tissue dies. A nationwide registry study from the University of Oulu is the first in Finland to measure how common it is in these patients.
The study
Researchers combined data from the Finnish Institute for Health and Welfare (THL) and the Social Insurance Institution of Finland (Kela). They included 652 breast cancer patients with bone metastases who received antiresorptive treatment between 2013 and 2015, and followed them until the end of 2020.
The results
- Jaw osteonecrosis was diagnosed in 12.6% of patients treated with denosumab alone.
- The figure was 15.3% in patients who first received bisphosphonates and then switched to denosumab.
- Only a small proportion of patients treated with bisphosphonates alone developed the condition.
Dental procedures linked to oral infection, especially tooth extraction and root canal treatment, were associated with higher risk. The number of root canal patients was small, so this does not show that the procedure itself causes the condition.
What it means
The authors stress that the findings do not justify stopping antiresorptive treatment or withholding needed dental care. Doctoral researcher Miika Kujanpää said sources of oral infection should be found and treated before therapy starts, with oral health monitored throughout, through close collaboration between oncology and dental teams.
Sources: News-Medical (University of Oulu), ecancer
This story is relayed from the source named above; responsibility for its content rests with the original source.
FAQ
What is medication-related osteonecrosis of the jaw?
Medication-related osteonecrosis of the jaw is a condition in which jawbone tissue dies, and it is a known side effect of antiresorptive drugs such as denosumab and bisphosphonates.
How common was jaw osteonecrosis with denosumab in the Finnish study?
In the Finnish study, jaw osteonecrosis was diagnosed in 12.6% of breast cancer patients treated with denosumab alone and in 15.3% of those who switched from bisphosphonates to denosumab.
Which dental procedures were linked to jaw osteonecrosis risk?
Tooth extraction and root canal treatment were associated with a higher risk of jaw osteonecrosis in the Finnish study, although root canal cases were few.
Should breast cancer patients stop denosumab because of jaw osteonecrosis risk?
No, the Finnish researchers say the findings do not justify stopping antiresorptive treatment; benefits and risks should be assessed individually.
How can jaw osteonecrosis risk be reduced in cancer patients?
The Finnish researchers advise finding and treating sources of oral infection before antiresorptive therapy begins and monitoring oral health throughout treatment.


